CDKN1A and breast carcinoma: This compound has shown potential in inducing G2/M cell cycle arrest and apoptosis in MCF-7 breast cancer cells and exhibits synergistic effects with doxorubicin in inhibiting SKBR-3 breast cancer cell proliferation by modulating cyclin-dependent kinase inhibitor 1 (Cunha et al., 2016).